Mallinckrodt (MNK) Surpasses Q4 Earnings and Revenue Estimates
Mallinckrodt (MNK) came out with quarterly earnings of $2.40 per share, beating the Zacks Consensus Estimate of $2.05 per share. This compares to earnings of $2.18 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 17.07%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.98 per share when it actually produced earnings of $2.07, delivering a surprise of 4.55%.
Over the last four quarters, the company has surpassed consensus EPS estimates four times.
Mallinckrodt, which belongs to the Zacks Medical - Generic Drugs industry, posted revenues of $804.90 million for the quarter ended December 2019, surpassing the Zacks Consensus Estimate by 3.99%. This compares to year-ago revenues of $834.90 million. The company has topped consensus revenue estimates two times over the last four quarters.
The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.
Mallinckrodt shares have added about 19.5% since the beginning of the year versus the S&P 500's decline of -0.2%. |